Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...
CALGARY, AB, Aug. 15, 2025 /CNW/ - Tamarack Valley Energy Ltd. ("Tamarack" or the "Company") (TSX: TVE) is pleased to announce the declaration of its...
LOS ANGELES, Aug. 15, 2025 /PRNewswire/ -- "Empowered with Meg Ryan" joins forces with the Charlotte Rescue Mission to explore the profound impact of...
Flexible financing options for roofing contractors, including no credit check programs, to prepare crews, materials, and equipment ahead of Storm Season 2025.
Flexible financing options for roofing contractors, including no credit check programs, to prepare crews, materials, and equipment ahead of Storm Season 2025.
ROK Financial reports rising interest in flexible business lines of credit as small and mid-sized companies seek faster, more adaptable funding options in 2025.
ROK Financial reports rising interest in flexible business lines of credit as small and mid-sized companies seek faster, more adaptable funding options in 2025.
As Millennials and Gen Z face soaring interest rates, record balances, and delayed financial milestones, Consolidated Credit finds demand for counseling spikes.
FORT LAUDERDALE, Fla.,...
Reports record profits, with the financial statements reflecting accelerated growth and high profitability, whilst maintaining financial stability
TEL AVIV, Israel , Aug. 11, 2025 /PRNewswire/ -- First...